Varta
← Back to stories

From NDTV

Center-Right Owned by Adani Group (AMG Media)

AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Late-Stage Trial

AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Late-Stage Trial

RSS excerpt

Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and $5 billion. It targets a protein found in the lining of the stomach that's expressed in some gastric cancers.

✦ Single Source 1 news outlet reporting

Fact-Check & Bias Analysis

Reported by a single newsroom so far. Other outlets have not independently corroborated this story yet.

Coverage Bias Distribution

Based on 1 reporting publisher
Left / Center-Left 0 (0%)
Center 0 (0%)
Center-Right / Right 1 (100%)

Read more news

See all latest stories →